Aclaris Therapeutics Stock Analysis

Aclaris Stock Analysis Notes

About 96.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.55. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aclaris Therapeutics recorded a loss per share of 1.27. The entity had not issued any dividends in recent years. Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. Aclaris Therapts operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 72 people. For more info on Aclaris Therapeutics please contact Neal Walker at 484 324 7933 or go to https://www.aclaristx.com.

Aclaris Therapeutics Investment Alerts

Aclaris Therapeutics Upcoming and Recent Events

Aclaris Largest EPS Surprises

View All Earnings Estimates

Aclaris Stock Institutional Investors

Note, although Aclaris Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Aclaris Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 87.24 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Aclaris Therapeutics's market, we take the total number of its shares issued and multiply it by Aclaris Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Aclaris Profitablity

The company has Profit Margin (PM) of (2.83) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.35) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.35.

Management Efficiency

Aclaris Therapeutics has return on total asset (ROA) of (0.3253) % which means that it has lost $0.3253 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4988) %, meaning that it created substantial loss on money invested by shareholders. Aclaris Therapeutics' management efficiency ratios could be used to measure how well Aclaris Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.47 in 2024. Return On Capital Employed is likely to drop to -0.61 in 2024. At this time, Aclaris Therapeutics' Non Current Assets Total are comparatively stable compared to the past year. Total Current Assets is likely to gain to about 139.1 M in 2024, whereas Other Current Assets are likely to drop slightly above 5.7 M in 2024.

Technical Drivers

As of the 19th of April, Aclaris Therapeutics shows the Risk Adjusted Performance of 0.0341, mean deviation of 2.77, and Downside Deviation of 3.88. Aclaris Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Aclaris Therapeutics, which can be compared to its peers. Please confirm Aclaris Therapeutics downside deviation, jensen alpha, as well as the relationship between the Jensen Alpha and downside variance to decide if Aclaris Therapeutics is priced correctly, providing market reflects its regular price of 1.24 per share. Given that Aclaris Therapeutics is a hitting penny stock territory we recommend to closely look at its total risk alpha.

Aclaris Therapeutics Price Movement Analysis

Aclaris Therapeutics Insider Trading Activities

Aclaris Therapeutics Predictive Daily Indicators

Aclaris Therapeutics Forecast Models

Aclaris Therapeutics' time-series forecasting models are one of many Aclaris Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Aclaris Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Aclaris Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Aclaris shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Aclaris Therapeutics. By using and applying Aclaris Stock analysis, traders can create a robust methodology for identifying Aclaris entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Aclaris analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Aclaris analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Aclaris Therapeutics stock analysis indicators help investors evaluate how Aclaris Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Aclaris Therapeutics shares will generate the highest return on investment. By understating and applying Aclaris Therapeutics stock analysis, traders can identify Aclaris Therapeutics position entry and exit signals to maximize returns.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aclaris Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Aclaris Stock please use our How to Invest in Aclaris Therapeutics guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.

Is Aclaris Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aclaris Therapeutics. If investors know Aclaris will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aclaris Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Aclaris Therapeutics is measured differently than its book value, which is the value of Aclaris that is recorded on the company's balance sheet. Investors also form their own opinion of Aclaris Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aclaris Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aclaris Therapeutics' market value can be influenced by many factors that don't directly affect Aclaris Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Aclaris Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aclaris Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aclaris Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.